See more : APA Corporation (0HGC.L) Income Statement Analysis – Financial Results
Complete financial analysis of Zomedica Corp. (ZOM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zomedica Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Unjha Formulations Limited (UNJHAFOR.BO) Income Statement Analysis – Financial Results
- Dragon Mountain Gold Limited (DMG.AX) Income Statement Analysis – Financial Results
- AdvanceTC Limited (ATCLF) Income Statement Analysis – Financial Results
- Inter Cars S.A. (CAR.WA) Income Statement Analysis – Financial Results
- Watkin Jones Plc (WJG.L) Income Statement Analysis – Financial Results
Zomedica Corp. (ZOM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zomedica.com
About Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.19M | 18.93M | 4.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.87M | 5.28M | 1.08M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.32M | 13.65M | 3.05M | -530.02K | -787.61K | -205.77K | -92.41K | -45.82K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 68.76% | 72.12% | 73.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.74M | 2.58M | 1.67M | 8.04M | 10.35M | 10.32M | 2.75M | 1.52M | 758.05K | 0.00 | 0.00 |
| General & Administrative | 29.03M | 22.93M | 0.00 | 7.93M | 8.18M | 5.83M | 5.08M | 4.24M | 1.43M | 42.41K | 77.50K |
| Selling & Marketing | 14.14M | 9.88M | 0.00 | 261.91K | 471.89K | 225.89K | 164.25K | 194.19K | 143.47K | 0.00 | 0.00 |
| SG&A | 43.17M | 33.00M | 22.75M | 8.19M | 8.65M | 6.06M | 5.24M | 4.43M | 1.57M | 42.41K | 77.50K |
| Other Expenses | 0.00 | -7.00K | 6.00K | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.91M | 35.58M | 24.43M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Cost & Expenses | 56.78M | 40.85M | 25.51M | 16.76M | 19.78M | 16.58M | 8.08M | 6.00M | 2.28M | 42.41K | 77.50K |
| Interest Income | 5.46M | 2.70M | 357.45K | 32.86K | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 175.00K | 1.00K | 6.05K | 732.00 | 18.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.30M | 4.04M | 1.14M | 530.02K | 787.61K | 205.77K | 92.41K | 45.82K | 9.05K | 0.00 | 0.00 |
| EBITDA | -29.39M | -15.34M | -19.57M | -16.38M | -19.00M | -16.44M | -7.97M | -5.97M | -2.28M | -42.41K | -77.50K |
| EBITDA Ratio | -116.68% | -80.23% | -479.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.59M | -21.92M | -21.37M | -16.76M | -19.78M | -16.58M | -8.08M | -6.00M | -2.29M | -42.41K | -77.50K |
| Operating Income Ratio | -125.43% | -115.81% | -517.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.27M | 2.54M | 657.78K | -146.81K | 273.00 | -68.44K | 18.98K | 258.06K | 7.44K | 0.00 | 0.00 |
| Income Before Tax | -35.86M | -19.38M | -20.72M | -16.91M | -19.78M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Income Before Tax Ratio | -142.38% | -102.38% | -501.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.33M | -2.37M | -2.33M | 9.33K | 38.08K | 136.88K | -18.98K | 28.59K | 0.00 | 0.00 | 0.00 |
| Net Income | -34.53M | -17.02M | -18.38M | -16.92M | -19.82M | -16.65M | -8.07M | -6.01M | -2.28M | -42.41K | -77.50K |
| Net Income Ratio | -137.10% | -89.88% | -444.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| EPS Diluted | -0.04 | -0.02 | -0.02 | -0.05 | -0.19 | -0.18 | -0.09 | -0.08 | -0.05 | -0.04 | -0.23 |
| Weighted Avg Shares Out | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 92.49M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
| Weighted Avg Shares Out (Dil) | 979.95M | 979.92M | 956.53M | 364.44M | 106.30M | 93.44M | 87.40M | 80.16M | 46.23M | 1.00M | 336.99K |
Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for...
Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities
CE Mark approval opens European market for TRUVIEW system ANN ARBOR, MI / ACCESSWIRE / September 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and...
Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product
Assisi's tPEMF™ technology aligns with Fear Free's mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI / ACCESSWIRE / August 29, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering...
Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System
Increased functionality makes the VETGuardian system a must have for veterinarians ANN ARBOR, MI / ACCESSWIRE / August 22, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for...
More Than $9M Bet On Nerdy? Check Out These 3 Penny Stocks Executives Are Aggressively Buying
The Dow Jones index closed lower by more than 50 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
Leading veterinary experts to present at the Fetch dvm360 Veterinary Conference in Kansas City, August 23-25, 2024 ANN ARBOR, MI / ACCESSWIRE / August 20, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering...
Zomedica Corp. (ZOM) Q2 2024 Earnings Call Transcript
Zomedica Corp. (NYSE:ZOM ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Larry Heaton - CEO Peter Donato - CFO Conference Call Participants Andrew Rem - Odinson Partners Operator Good afternoon, ladies and gentlemen, and...
Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported...
Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica ® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics...
Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only...
Source: https://incomestatements.info
Category: Stock Reports
How has Zomedica’s diagnostic product revenue grown?
Zomedica (NYSE:ZOM) reported Q3 2024 financial results with revenue growing 10% to $7.0 million, maintaining a strong gross margin of 72.3%. The Diagnostics segment grew 38%, while the Therapeutic Device segment increased 9%.
What were Zomedica’s revenue and losses in the last 12 months?
In the last 12 months, Zomedica had revenue of $26.73 million and -$62.19 million in losses. Loss per share was -$0.06.